Proteomic analysis of the human brain in huntington’s disease indicates pathogenesis by molecular processes linked to other neurodegenerative diseases and to type-2 diabetes

Journal of Huntington's Disease

Volumn 2, Issue 1, 2013, Pages 89-99

  Schönberger, Sarah J ^a   Jezdic, Dina ^a,c   Faull, Richard L M ^c   Cooper, Garth J S ^a,b,c,d,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Copper; Dementia; Experimental therapeutics; Human brain; Metabolic stress; Oxidative stress; Type 2 diabetes

Indexed keywords

COPPER;

AGED; ARTICLE; BRAIN; CASE CONTROL STUDY; DEGENERATIVE DISEASE; DEMENTIA; EXPERIMENTAL THERAPEUTICS; FEMALE; HUMAN; HUMAN BRAIN; HUNTINGTON CHOREA; MALE; METABOLIC STRESS; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PEPTIDE MAPPING; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; TYPE-2 DIABETES; VERY ELDERLY;

COPPER; DEMENTIA; EXPERIMENTAL THERAPEUTICS; HUMAN BRAIN; METABOLIC STRESS; OXIDATIVE STRESS; TYPE-2 DIABETES;

AGED; AGED, 80 AND OVER; BRAIN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PEPTIDE MAPPING; PROTEOMICS;

EID: 84906923428     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-120044     Document Type: Article

References (64)

1. Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, et al. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: A model of Huntington disease. Mol Cell Proteomics. 2005; 4(12): 1849-61.
2. The Huntington’s Disease Collaborative Research Group. Anovel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6): 971-83.
3. Zabel C, Mao L, Woodman B, Rohe M, Wacker MA, Klare Y, et al. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Mol Cell Proteomics. 2009;8(4): 720-34.
4. Liu X, Miller BR, Rebec GV, Clemmer DE. Protein expression in the striatum and cortex regions of the brain for a mouse model of Huntington’s disease. J Proteome Res. 2007;6(8): 3134-42.
5. Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med. 2008;45(5): 667-78.
6. Rosas HD, Salat DH, Lee SY, Zaleta AK, PappuV, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington’s disease: Complexity and heterogeneity. Brain: A Journal of Neurology. 2008;131(Pt 4): 1057-68.
7. van Roon-Mom WM, Reid SJ, Jones AL, MacDonald ME, Faull RL, Snell RG. Insoluble TATA-binding protein accumulation in Huntington’s disease cortex. Brain Res Mol Brain Res. 2002;109(1-2): 1-10.
8. Blumenstein M, McMaster MT, Black MA, Wu S, Prakash R, Cooney J, et al. A proteomic approach identifies early pregnancy biomarkers for preeclampsia: Novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics. 2009;9(11): 2929-45.
9. Edgar PF, Schonberger SJ, Dean B, Faull RL, Kydd R, Cooper GJ. A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer’s disease individuals. Mol Psychiatry. 1999;4(2): 173-8.
10. Schonberger SJ, Edgar PF, Kydd R, Faull RL, Cooper GJ. Proteomic analysis of the brain in Alzheimer’s disease: Molecular phenotype of a complex disease process. Proteomics. 2001;1(12): 1519-28.
11. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington’s disease brain. Hum Mol Genet. 2006;15(6): 965-77.
12. Borrell-Pages M, Zala D, Humbert S, Saudou F. Huntington’s disease: From huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci. 2006;63(22): 2642-60.
13. Goswami A, Dikshit P, Mishra A, Mulherkar S, Nukina N, Jana NR. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun. 2006;342(1): 184-90.
14. Bonifati V, Oostra BA, Heutink P. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson’s disease. J Mol Med. 2004;82(3): 163-74.
15. Tchaikovskaya T, Fraifeld V, Urphanishvili T, Andorfer JH, Davies P, Listowsky I. Glutathione S-transferase hGSTM3 and ageing-associated neurodegeneration: Relationship to Alzheimer’s disease. Mech Ageing Dev. 2005;126(2): 309-15.
16. CalabreseV, Stella AM, ButterfieldDA, Scapagnini G. Redox regulation in neurodegeneration and longevity: Role of the heme oxygenase and HSP70 systems in brain stress tolerance. Antioxid Redox Signal. 2004;6(5): 895-913.
17. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington’s disease mutation. J Biol Chem. 2002;277(37): 33791-8.
18. Huen NY, Chan HY. Dynamic regulation of molecular chaperone gene expression in polyglutamine disease. Biochem Biophys Res Commun. 2005;334(4): 1074-84.
19. Wyttenbach A. Role of heat shock proteins during polyglutamine neurodegeneration: Mechanisms and hypothesis. J Mol Neurosci. 2004;23(1-2): 69-96.
20. Hickey MA, Chesselet MF. Apoptosis in Huntington’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(2): 255-65.
21. Rego AC, Oliveira CR. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: Implications for the pathogenesis of neurodegenerative diseases. Neurochem Res. 2003;28(10): 1563-74.
22. Fan J, Ren H, Jia N, Fei E, ZhouT, Jiang P, et al. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem. 2008;283(7): 4022-30.
23. Berry MD. Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders. J Psychiatry Neurosci. 2004;29(5): 337-45.
24. Mazzola JL, Sirover MA. Alteration of nuclear glyceraldehyde-3-phosphate dehydrogenase structure in Huntington’s disease fibroblasts. Brain Res Mol Brain Res. 2002;100(1-2): 95-101.
25. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J. Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol. 2003;28(1): 51-64.
26. Marangos PJ, Paul SM. Brain levels of neuron-specific and nonneuronal enolase in Huntington’s disease. J Neurochem. 1981;37(5): 1338-40.
27. Iwangoff P, Armbruster R, Enz A, Meier-RugeW. Glycolytic enzymes from human autoptic brain cortex: Normal aged and demented cases. Mech Ageing Dev. 1980;14(1-2): 203-9.
28. Sultana R, Boyd-Kimball D, Cai J, PierceWM, Klein JB, Merchant M, et al. Proteomics analysis of the Alzheimer’s disease hippocampal proteome. J Alzheimers Dis. 2007;11(2): 153-64.
29. Singaraja RR, Hadano S, Metzler M, Givan S, Wellington CL, Warby S, et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet. 2002;11(23): 2815-28.
30. Sirover MA. Minireview. Emerging new functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. Life Sci. 1996;58(25): 2271-7.
31. DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA. Early changes in Huntington’s disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol. 2004;33(5): 517-33.
32. Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci. 2004;24(1): 269-81.
33. Ralser M, Nonhoff U, Albrecht M, Lengauer T, Wanker EE, Lehrach H, et al. Ataxin-2 and huntingtin interact with endophilin-A complexes to function in plastin-associated pathways. Hum Mol Genet. 2005;14(19): 2893-909.
34. Engqvist-Goldstein AE, Kessels MM, Chopra VS, Hayden MR, Drubin DG. An actin-binding protein of the Sla2/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles. J Cell Biol. 1999;147(7): 1503-18.
35. Bamburg JR. Proteins of the ADF/cofilin family: Essential regulators of actin dynamics. Annu Rev Cell Dev Biol. 1999;15: 185-230.
36. Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM, et al. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington’s disease. J Neurosci. 2007;27(16): 4424-34.
37. Bamburg JR, BernsteinBW, Davis RC, Flynn KC, Goldsbury C, Jensen JR, et al. ADF/Cofilin-actin rods in neurodegenerative diseases. Curr Alzheimer Res. 2010;7(3): 241-50.
38. Li H, Li SH, Yu ZX, Shelbourne P, Li XJ. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington’s disease mice. J Neurosci. 2001;21(21): 8473-81.
39. Ardley HC, Hung CC, Robinson PA. The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Letters. 2005;579(3): 571-6.
40. Ross CA, Pickart CM. The ubiquitin-proteasome pathway in Parkinson’s disease and other neurodegenerative diseases. Trends Cell Biol. 2004;14(12): 703-11.
41. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, et al. Global changes to the ubiquitin system in Huntington’s disease. Nature. 2007;448(7154): 704-8.
42. Hague SM, Klaffke S, Bandmann O. Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease. J Neurol Neurosurg Psychiatry. 2005;76(8): 1058-63.
43. Grune T, Jung T, Merker K, Davies KJ. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and ‘aggresomes’ during oxidative stress, aging, and disease. Int J Biochem Cell Biol. 2004;36(12): 2519-30.
44. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation. J Neurosci. 2007;27(13): 3571-83.
45. Layfield R, Lowe J, Bedford L. The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem. 2005;41: 157-71.
46. Charrin BC, Saudou F, Humbert S. Axonal transport failure in neurodegenerative disorders: The case of Huntington’s disease. Pathol Biol. 2005;53(4): 189-92.
47. Hoffner G, Kahlem P, Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: Relevance to Huntington’s disease. J Cell Sci. 2002;115(Pt 5): 941-8.
48. Hirabayashi M, Inoue K, Tanaka K, Nakadate K, Ohsawa Y, Kamei Y, et al. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ. 2001;8(10): 977-84.
49. Bird ED, Gale JS, Spokes EG. Huntington’s chorea: Post mortem activity of enzymes involved in cerebral glucose metabolism. J Neurochem. 1977;29(3): 539-45.
50. Tellez-Nagel I, Johnson AB, Terry RD. Studies on brain biopsies of patients with Huntington’s chorea. J Neuropathol Exp Neurol. 1974;33(2): 308-32.
51. Lumsden AL, Henshall TL, Dayan S, Lardelli MT, Richards RI. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet. 2007;16(16): 1905-20.
52. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366(9503): 2112-7.
53. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7(4): 278-94.
54. Launer LJ. Demonstrating the case that AD is a vascular disease: Epidemiologic evidence. Ageing Res Rev. 2002; 1(1): 61-77.
55. Brain PathologyMartinez A, Portero-Otin M, Pamplona R, Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol. 2010;20(2): 281-97.
56. Gong D, Lu J, Chen X, Reddy S, Crossman DJ, Glyn-Jones S, et al. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia. 2008;51(9): 1741-51.
57. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53(2): 474-81.
58. Josefsen K, Nielsen MD, Jorgensen KH, Bock T, Norremolle A, Sorensen SA, et al. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington’s disease. J Neuroendocrinol. 2008;20(2): 165-72.
59. Cooper GJ, Chan YK, Dissanayake AM, Leahy FE, Keogh GF, Frampton CM, et al. Demonstration of a hyperglycemiadriven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: Quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes. 2005;54(5): 1468-76.
60. Hands SL, Mason R, Sajjad MU, Giorgini F, Wyttenbach A. Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington’s disease. Biochem Soc Trans. 2010;38(2): 552-8.
61. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2003;100(19): 11065-9.
62. Fraústo da Silva JJ, Williams RJ. The Biological Chemistry of the Elements: The Inorganic Chemistry of Life. Oxford, U.K.: Clarendon Press; 2001.
63. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes. 2004;53(9): 2501-8.
64. Jüllig M, Hickey AJ, Crossman DJ, Xu A, et al. Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)- selective chelator. Proteomics Clin Appl. 2007;1: 387-99.